Instil Bio, Inc.

NASDAQ:TIL

Biotechnology

Healthcare
$7.45 +0.13%

+$0.01 today

Market cap
$50.53M
Beta
1.91
P/E (TTM)
-1.1
EPS (TTM)
-$6.99
52W Low $5.67High $33.83

Volume 0.02M

Average 0.03M

TIL Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Instil Bio, Inc.NASDAQ: TIL

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation declines year over year

Q1 FY2026 stock-based compensation of $985K fell 71.8% year over year, behind the -61.9% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 38.7% from the prior quarter. Over 3 fiscal years it compounded at -34.1% a year.

Context

  • Stock-based compensation increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -71.8% toward the trailing-twelve-month pace of -61.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$985K-38.7% QoQ
Last fiscal yearDec 2025
$8.69M-49.6% YoY
LTMMar 2026
$6.18M-61.9% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-71.8%——
1 year-49.6%——
3-year CAGR-34.1%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
8.69M USD
Year-over-year change
-49.6%
4-year CAGR
-24.1%

Stock-Based Compensation vs competitors

How TIL compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -61.9% is the 7th highest of 9, against a peer median of -27.0%.
  • Over three fiscal years its annual growth of -34.1% compares with a peer median of +0.8%.
TIL Competitors
Stock-Based Compensation for TIL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PLRXPliant Therapeutics, Inc.LTM Mar 2026$21.58M USD-41.5%+5.1%—
ZNTLZentalis Pharmaceuticals, Inc.LTM Mar 2026$14.24M USD-76.6%-23.8%—
MGNXMacroGenics, Inc.LTM Mar 2026$12.55M USD-55.6%-11.3%8.0%
WHWKWhitehawk Therapeutics IncLTM Dec 2025$9.87M USD-8.9%+0.8%138.2%
STTKShattuck Labs, Inc.LTM Mar 2026$7.69M USD-12.5%+2.7%768.9%
ONCYOncolytics Biotech Inc.LTM Mar 2026CA$6.75M CAD+101.1%+21.4%—
TILInstil Bio, Inc.LTM Mar 2026$6.18M USD-61.9%-34.1%—
SRZNSurrozen, Inc.LTM Mar 2026$5.11M USD+30.3%-5.3%68.1%
IFRXInflaRx N.V.LTM Mar 2026€2.48M EUR-152.9%—8455.2%
Peer median (excluding TIL) —-27.0%+0.8%138.2%

Competitors are the stored peer set for TIL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(156.79M)(223.18M)(156.09M)(74.14M)(71.37M)
Depreciation & Amortization2.75M5.99M4.76M3.61M534K
Deferred Income Tax710K0000
Stock-Based Compensation26.2M30.44M18.17M17.26M8.69M
Change in Working Capital4.36M(9.57M)(9.02M)(12.61M)(560K)
Accounts Receivables0000(3.4M)
Inventory00000
Accounts Payables3.86M(1.81M)(1.13M)(556K)116K
Other Working Capital499K(7.76M)(7.89M)(12.05M)2.72M
Other Non-Cash Items636K16.15M60.15M10.18M26.09M
Operating Cash Flow(122.14M)(180.16M)(82.03M)(55.7M)(36.62M)
Capital Expenditures(57.83M)(84.59M)(20.66M)(10M)0
Acquisitions (Net)01.17M00432K
Purchases of Investments(1.11B)(666.22M)(301.47M)(135.6M)(100.86M)
Sales of Investments691M865.35M361.7M198.71M135.9M
Other Investing Activities0(1.17M)1.56M866K0
Investing Cash Flow(474.4M)114.54M41.13M53.97M25.48M
Debt Repayment070.34M8.08M2.76M6.61M
Common Stock Issued339.02M1.55M00853K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities1.69M00(1.01M)(172K)
Financing Cash Flow393.16M71.89M8.08M1.76M7.29M
Effect of Forex Changes(304K)(637K)(201K)(94K)20K
Net Change in Cash(203.67M)5.63M(33.02M)(61K)(3.83M)
Free Cash Flow(179.97M)(264.75M)(102.69M)(65.7M)(36.62M)

Instil Bio, Inc.

NASDAQ:TIL

Intrinsic Alpha fair value

Locked

Current Price

$7.45

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.